Novo Nordisk and Eli Lilly are testing their respective blockbuster weight loss injections as treatments for the same kind of liver disease, called nonalcoholic steatohepatitis, or NASH.

Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic fatty liver diseases (NAFLD) into more severe forms of liver disease by ...

Hypothyroidism, for example, might lead to NASH, cirrhosis and potentially liver cancer via the development of hyperlipidemia and obesity. Patients with growth hormone deficiency have a metabolic ...

Non-Alcoholic Fatty Liver Disease (NAFLD) is emerging as a significant global health concern, driven by increasing rates of obesity, diabetes and sedentary lifestyles. NAFLD includes a spectrum of ...

HepaStem is also advancing into the clinic in severe NASH. These studies mark the culmination of more than a decade of work to discover and refine liver specific cell-based therapies with ...